Education Blog for Healthcare Professionals

Posts Tagged ‘DVT’

Yasmin, Yaz and Other Drospirenone Contraceptives: Risk for VTE

| Uncategorized, Women and blood clots | Comments Off on Yasmin, Yaz and Other Drospirenone Contraceptives: Risk for VTE

It has long been known that estrogen-containing birth control preparations (pill, patch, ring) increase the risk for DVT and PE (venous thromboembolism = VTE).  This risk is partially due to the estrogen.  However, part of the risk is also due to the type of progestin in these preparations. Read the rest of this entry »

Pregnancy and Venous Thromboembolism: Prevention, Diagnosis, Treatment

| Uncategorized, Women and blood clots | 1 Comment »

A new guideline about the prevention, diagnosis, and treatment of DVT and PE associated with pregnancy was published today by ACOG (American College of Obstetricians and Gynecologists) in its respected series of Practice Bulletins.  The bulletin includes detailed reference to thromboprophylaxis in pregnant women with thrombophilia. Read the rest of this entry »

Incidentally Discovered DVT, PE or Other Clots

| Cancer and blood clots, Clots in unusual locations, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Uncategorized | 3 Comments »

General comments

CT or MRI scans will occasionally detect an incidental iliofemoral DVT, PE or intra-abdominal thrombosis (IVC, portal, splenic, mesenteric or renal vein). This is particularly common in cancer patients undergoing staging CT scans. When such an incidental, asymptomatic venous thromboembolism (VTE) is discovered, the question arises whether the patient should be treated with anticoagulants or not. Read the rest of this entry »

DVT and PE: How Long to Treat With Anticoagulants?

| Anticoagulants, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Therapy, Uncategorized | Comments Off on DVT and PE: How Long to Treat With Anticoagulants?

Explanation for Patients

The complex topic of “Length of Anticoagulant Treatment” for patients with VTE  is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here).

For the Health Care Professional

Well respected treatment guidelines exist [ref 1,2]. Read the rest of this entry »

Apixaban (Eliquis®) – Another New Oral Anticoagulant

| Anticoagulants, Therapy, Uncategorized | Comments Off on Apixaban (Eliquis®) – Another New Oral Anticoagulant

Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval Read the rest of this entry »

Acute Proximal DVT – Offering Patients Enrollment into ATTRACT Trial

| Deep Vein Thrombosis (DVT), Uncategorized | 2 Comments »

If you as a health care professional are involved in the management of patients with acute (proximal) DVT, please consider giving the patient (who has leg symptoms ≤ 14 days) an opportunity to be enrolled in the national ATTRACT trial (information on the trial is here).

This NIH-funded, multi-center trial investigates whether catheter-directed thrombectomy (± locally delivered tPA into the clot) Read the rest of this entry »